loading
loading
The results strengthen Eli Lilly’s prospects to enter the targeted KRAS G12C-mutated lung cancer market, indicating potential for a new initial treatment where no targeted therapies are currently approved. Olomorasib with Keytruda and chemotherapy achieved a 62% confirmed tumor response rate, with median responses lasting 14.5 months and median progression-free survival of 11.6 months. The findings lack randomized comparison groups, making it premature to conclude olomorasib’s superiority over existing treatments until further Phase 3 randomized trial results are available.
document fetched 2026-10-26 02:57 · canonical https://seekingalpha.com/news/4657011-eli-lilly-reports-promising-lung-cancer-drug-results?feed_item_type=news